Achillion Pharmaceuticals, Inc. Company Profile

Company Overview:

Achillion Pharmaceuticals is a development-stage biopharmaceutical company. It is engaged in discovering, developing and commercializing treatments for infectious diseases. Within the anti-infective market, the company concentrates on the development of antivirals for the treatment of chronic hepatitis C and the development of antibacterials for the treatment of resistant bacterial infections. The company operates in the US.

Achillion discovered and developed a comprehensive portfolio of antivirals for the treatment of HCV, including a unique second-generation NS5A inhibitor, odalasvir (also known as ACH-3102); a novel nucleotide NS5B polymerase inhibitor, ACH-3422; and a NS3 protease inhibitor, sovaprevir.

The potential of Achillion’s three lead HCV candidates has been validated by a worldwide license and collaboration agreement with Janssen Pharmaceuticals worth up to $905 million in milestones plus mid-teen to low-twenties percentage royalties on worldwide sales.

Scope of the Report

• About the Company - Historical Details, Current Ownership Structure and basic overview of Achillion Pharmaceuticals, Inc. in terms of revenue, net income, and operating income.
• Financials - Details about Achillion Pharmaceuticals, Inc. listing status, annual financial reports (for the past 5 years), key financial highlights and region wise and category wise breakdown of their net revenue.
• Products / Services - Listing of the company’s entire portfolio along with description of individual products / services providing a clear picture of their target audience.
• Company SWOT Analysis - Outlines Achillion Pharmaceuticals, Inc.’s strengths, weaknesses, and opportunities and threats facing the company.
• Recent Developments - Showcases Achillion Pharmaceuticals, Inc.’s recent developments including mergers, acquisitions, partnerships, collaborations, new product launches, investment and divestment plans.
• Strategic Evaluation - Provides an overview of Achillion Pharmaceuticals, Inc.’s corporate goals and strategic initiatives and evaluates their outcomes along with outlining any persisting legal issues and outlook of our in-house analyst panel on the particular company.
• Technology Landscape - Details how the company allocates its IT budget across the core areas of its business, CIO/CTO Profile, Key IT Initiatives and Deals undertaken buy the company at present along with outlook.

Key Questions Answered

• What domain does Achillion Pharmaceuticals, Inc. operate and what are key points about it?
• What is the product / service portfolio of Achillion Pharmaceuticals, Inc.?
• How has Achillion Pharmaceuticals, Inc. performed financially from the 2013?
• How does Achillion Pharmaceuticals, Inc. rank among its peers in terms of revenue and market share?
• What are Achillion Pharmaceuticals, Inc. strengths and weaknesses and what opportunities and threats does it face?
• What are Achillion Pharmaceuticals, Inc.’s main growth strategies and how successful has the company been at implementing them?
• What is the in-house technical capability of Achillion Pharmaceuticals, Inc.? Where does it procure / outsource it?

Reasons to buy

• Report delivered in easily accessible PPT format which can be used to gain insights quickly and further prepare presentations of your own
• Lean pricing structure ultimately giving you vast access to the unlimited knowledge repository of the company profiles at very competitive cost
• 12 hour delivery time fulfilling your urgent requests as per your requirement
• On-demand customization options that can completely cater to your needs by focusing the report onto given specifics